Lipid-based nanoparticles are pivotal in modern medicine, improving drug delivery and mRNA therapies through innovative ...

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors. Research reported recently in the journal Nature ...

The U.S. government is turning its back on a medical breakthrough that has saved millions of lives, halting $500 million in federal funding to develop new mRNA vaccines against potentially ...

Ionis Pharmaceuticals, Inc. shows promise with new drug launches and a robust pipeline. Click here to read IONS stock ...

Q3 2025 Earnings Call Transcript November 3, 2025 BioNTech SE misses on earnings expectations. Reported EPS is $-0.14 EPS, expectations were $0.75. Operator: Welcome to BioNTech’s Third Quarter 2025 ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

The start of the trial marks an expansion of the firm's oncology pipeline, and the firm hopes mRNA-2808 will be the first of many T-cell engagers in its portfolio.

Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the ...

Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.

Moderna (MRNA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

Moderna’s market value has fallen by more than 90% — $185 billion, or a full Sony — from its 2021 peak to around $10 billion ...